HCA Healthcare, Inc.
$138.89B- Market cap
- $93.44B
- Debt
- +$46.49B
- Cash
- −$1.04B
Capital structure 67% equity / 33% debt · EV / Revenue 1.84x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: HCA stock price at discount vs DHR $421.21 current versus $1.12K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Implied fair value · at HCA's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 67% equity / 33% debt · EV / Revenue 1.84x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 88% equity / 12% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$171.11
Base
$241.68
Bull
$336.89
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
AGILENT TECHNOLOGIES, INC.
HCA vs A
ILLUMINA, INC.
HCA vs ILMN
JOHNSON & JOHNSON
HCA vs JNJ
ABBOTT LABORATORIES
HCA vs ABT
LOEWS CORP
HCA vs L
BERKSHIRE HATHAWAY INC
HCA vs BRK-B
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA’s lower-margin healthcare services model deserves only a modest discount to DHR rather than a large one, then HCA looks interesting on a relative basis; however, if you think DHR’s superior margins and profitability deserve a persistent premium, then the current price gap is mostly justified rather than an outright bargain.
HCA trades at a steep discount to DHR across P/E, P/S, EV/EBITDA, and EV/Revenue, while its current price sits near the lower end of its historical band. The implied P/E valuation of $1110.37 suggests large upside, but that figure is anchored to a DHR with structurally superior margins and a very different industrial/healthcare tools profile.
Supporting Metrics